Halt Medical, Inc. Announces Podium Presentations at the 45th Annual AAGL Global Congress on Minimally Invasive Gynecology Meeting

November 14, 2016


BRENTWOOD, Calif.–(BUSINESS WIRE)– Halt Medical, Inc., a privately held medical device company which develops minimally invasive, uterine sparing solutions for women who suffer from symptomatic fibroids, today announced five abstracts on the Acessa System will be presented orally at the 45th Annual Global Congress on Minimally Invasive Gynecology Meeting, being held November 14-18 in Orlando, Florida.

New Instrumentation or Technology on November 16, 2016 from 12:10 PM – 12:48 PM

  • Dr. Nicole Williams, Gynecology Institute of Chicago, will present two abstracts on post-market outcomes and ultrasound evaluations after radiofrequency ablation of symptomatic uterine fibroids
  • Dr. Keith Isaacson, Director of Minimally Invasive Gynecology at Newton-Wellesley, will present clinical outcomes at three years from the LUSTOR Study, a randomized controlled clinical trial of Acessa vs. Myomectomy
  • Dr. Kelly Braun, Associate Professor Augusta University, will present on ten surgeons’ early experience and proficiency using the first generation Acessa System in just two to five procedures

New Instrumentation or Technology on November 17, 2016 from 2:47 PM – 2:53 PM

  • Dr. Bruce Lee, inventor of the Acessa System, will present on the safe and effective use of radiofrequency ablation of uterine fibroids in symptomatic patients with uteri 15-weeks gestational size and greater

Dr. Nicole Williams at the Gynecology Institute of Chicago stated, “I have treated well over 100 patients with Acessa and have been very satisfied with the results. Equally important, Acessa has given the patients in my practice facing hysterectomy an alternative. In most cases, there is no need to remove the uterus. Acessa allows me to treat the underlying problem (the fibroids), while leaving an otherwise healthy organ unharmed.” This week, Dr. Williams will share real-world, post-operative outcomes after the treatment of 81 women with symptomatic fibroids.

What are uterine fibroids?

Uterine fibroids are benign, muscular tumors in a woman’s uterus that can cause heavy bleeding, painful periods, pressure, and distension of the abdomen [1]. At least 70% of women in the U.S. will develop fibroids by the age of 50, with the prevalence even higher among African-American women [2]. As a result, they remain a major women’s health issue with significant economic and reproductive impact. The NIH has determined that direct health care costs for the surgical treatment of fibroids are more than $2.1 billion annually [3]. In a nationwide inpatient sample, over half a million women underwent hysterectomy for benign gynecologic conditions [4] and the American Congress of Obstetricians and Gynecologists (ACOG) states that 39% of all hysterectomies are due to fibroids [5]. Over time, patients and gynecologists are turning to less invasive procedures, and laparoscopic options are becoming more popular [6].

The Acessa System is a minimally invasive, uterine conserving, laparoscopic procedure that delivers radiofrequency energy to destroy the fibroids. After treatment, the fibroid is reabsorbed by the surrounding tissue. The procedure allows the surgeon to treat only the fibroids, while preserving normal function of the uterus. Patients typically go home the same day with minimal discomfort, and enjoy a rapid return to normal activities.

About Halt Medical, Inc. – The Company is focused on establishing a new standard of care for women with symptomatic uterine fibroids. The Acessa System is cleared by the FDA and has CE mark for use in percutaneous, laparoscopic coagulation and ablation of soft tissue, including treatment of symptomatic uterine fibroids under laparoscopic ultrasound guidance. The Company is located in Brentwood, CA. For information about the Acessa System, please visit www.acessaprocedure.com.


  1. www.womenshealth.gov
  2. Baird DD et al. High Cumulative Incidence of Uterine Leiomyoma in Black and White Women: Ultrasound Evidence. Am J Obstet Gynecol 2003; 188 (1):100-107.
  3. National Institutes of Health fact sheet: http://report.nih.gov/nihfactsheets/viewfactsheet.aspx?csid=50
  4. Jacoby VL, Autry A, Jacobson G, Domush R, Nakagawa S, Jacoby A. Nationwide Use of Laparoscopic Hysterectomy Compared with Abdominal and Vaginal Approaches. Obstet Gynecol 2009;114(5):1041-1048.
  5. www.ACOG.org. 2011 Women’s Health Stats and Facts: p.18.
  6. Twijnstra AR, Kolkman W, Trimbos-Kemper GC, Jansen FW. Implementation of Advanced Laparoscopic Surgery in Gynecology: National Overview of Trends. J Minim Invasive Gynecol 2010;17(4):487-492.


Halt Medical, Inc.
Investor Relations:
Jeremy McFadden, 925-348-9911

- Enter Your Location -
- or -